



Independent Financial Adviser to QT Vascular Ltd in relation to the Interested Person Transaction General Mandate

On 15 April 2021, QT Vascular Ltd (the “**Company**” and together with its subsidiaries, the “**Group**”) released a circular seeking the approval of independent shareholders of the Company (the “**Independent Shareholders**”) for the adoption of a general mandate for interested person transactions (the “**Proposed IPT General Mandate**”) in respect of transactions that the Group expects to enter into with Expanse Medical Inc. (“**Expanse Medical**”). The Proposed IPT General Mandate would allow the Group to have the flexibility to redeploy its excess capacity as and when it arises by allowing the use of its excess manpower and/or excess office and laboratory facilities under the terms of the Proposed IPT General Mandate.

Eitan Konstantino, the Chief Executive Officer and Executive Director of the Company, is the sole director and shareholder of Expanse Medical. Accordingly, transactions entered into between an entity in the Group and Expanse Medical will be regarded as interested person transactions within the meaning of Chapter 9 of the Catalist Rules. Expanse Medical is a vehicle used by Eitan Konstantino for the development of certain medical devices and products undertaken in his personal capacity, with the knowledge and consent of the Board. Expanse Medical, as part of its business, may from time to time need to undertake activities which may require, *inter alia*, the use of manpower and/or office and laboratory facilities for such activities, similar to that currently being maintained by the Group.

The Proposed IPT General Mandate will encompass the following services to be provided by the Group to Expanse Medical:

- (a) the use of the Group’s office and laboratory facilities; and
- (a) the deployment of the Group’s finance and administrative staff for the provision of corporate, administrative and accounting support services.

SAC Capital Private Limited (“**SAC Capital**”) was appointed as the Independent Financial Adviser to the directors of the Company who are considered independent (the “**Non-Interested Directors**”) for the purposes of making a recommendation to the Independent Shareholders in respect of the Proposed IPT General Mandate. The circular, containing *inter alia*, SAC Capital’s opinion on the Proposed IPT General Mandate, the recommendation of the Non-Interested Directors and relevant information pertaining to the Proposed IPT General Mandate for the consideration of independent Shareholders, had been despatched to shareholders of the Company (the “**Shareholders**”) on 15 April 2021.

At the Extraordinary General Meeting held on 30 April 2021, the Company had received Shareholders’ approval for the resolution with respect to the Proposed IPT General Mandate.

For more information on our past transactions, click [here](#)

About SAC Capital

SAC Capital enjoys a long-standing reputation as a specialist in corporate finance, and we have been a trusted advisor to our clients and partners since 2004.

As an expert in the small-medium enterprise space across various disciplines – Initial Public Offerings (IPOs), mergers and acquisitions (M&As), corporate transactions for listed companies, underwriting and share placement, fund raising and Catalyst Sponsorship – we understand our clients' needs very well, and we are able to steer them in the right direction.

Financial Advisory - acting as FA and IFA

We provide financial advisory services for corporate exercises, taking into account the various compliance requirements, working alongside our clients to achieve their objectives.

Acting as Financial Adviser or Independent Financial Adviser, we have wide ranging experiences spanning Reverse Takeovers, General Offers, Interested Person Transactions and Delistings. The accumulated experiences from all the advisory engagements completed since 2004, numbering in excess of 150, gives us in depth knowledge of a broad spectrum of corporate advisory services.

Fundraising, M&A and Underwriting

Our Capital Markets (CM) unit assists our clients in fund-raising activities in both private and public equity markets. Our services include IPOs, secondary placements, rights issues, convertible bonds, pre-IPO financing, strategic equity and M&A. We deal with each client's specific requirements and provide customised capital markets solutions.

We are a leading placement agent and underwriter of equity and equity-linked offerings in Singapore, having completed offerings in the Lifestyle, Consumers, Healthcare, Technology, Media and Telecom (TMT), Real Estate, Manufacturing, Mineral, Oil and Gas (MOG) and Specialised Engineering sectors. Notwithstanding the above, the CM unit is sector agnostic with a wide range of expertise. CM unit also assists our clients in their communications with the equity markets.

Mainboard & Catalyst Listing

We advise our clients on equity fund raising which includes IPOs. Our work involves advising on, amongst others, restructuring exercises and compliance requirements of the Singapore Exchange and other regulatory authorities for the purpose of equity fund raising.

We also advise on Reverse Takeovers and secondary listings. We seek to understand our client's long term business plan and strategy so as to provide the appropriate advice to tailor to their needs and requirements.

Catalyst Sponsorship

We are one of the leaders in the market in the Catalyst Sponsorship space, with a view to support the growth of our sponsored issuers. Our principal scope of services as a Catalyst Sponsor is to advise and guide our sponsored issuers in relation to their continuing listing obligations, on an ongoing basis under the Catalyst Rules. Our experienced team of professionals work closely with the directors and management team of the sponsored issuers and assist them in disclosure and compliance matters for corporate actions and developments.

Research

With comprehensive knowledge of the local capital market, our experience and access to information means that the company is well placed to produce research reports. We seek to fill the gap in the industry where there is minimal research coverage for small and medium enterprises (SMEs) listed on the SGX. SAC Capital aims to provide a platform which assists investors in making informed decision when investing in these high-growth small/medium companies while promoting awareness and educating the general public of the merits of investing in listed SMEs.

Connect with us

SAC CAPITAL PRIVATE LIMITED

1 Robinson Road
#21-00 AIA Tower
Singapore 048542
Tel: +65 6232 3200
Fax: +65 6232 3244



[Visit us on our website](#)



[Visit us on LinkedIn](#)



[Email us for general enquiries](#)



[Email us for enquiries on our research offerings](#)